Cancer research in the era of immunogenomics
Introduction
Immunotherapy has emerged in the recent decade as a leading therapy against cancer, with therapies such as checkpoint immune blockade now commonly used against many tumours and sometimes given as a first-line therapy.1 The major immunotherapies commonly administrated target checkpoint molecules on tumour cells that suppress the activation of T cells2 3 (mainly CD8+...
How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies
Introduction
Triple-negative breast cancer (TNBC) is immunohistochemically defined by the lack of oestrogen receptor (ER), progesterone receptor and human epidermal growth factor receptor 2 (HER2) expression.1 2 Although it is generally more chemosensitive than other types of breast cancer, it is also characterised to harbour the most aggressive behaviour with the front-loaded risk of relapse...
ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016
ESMO/ASCO Global Curriculum Working Group
Chair
Christian Dittrich, MD, Professor of Medicine
Head of 3rd Medical Department—Centre for Oncology and Haematology, Kaiser Franz Josef-Spital, Vienna, Austria
Members
Emilio Alba Conejo, MD
Director of UGCI Oncology Intercentros, Hospital Universitario Virgen de la Victoria y Regional de Malaga, Malaga, Spain
Rossana Berardi, MD, Professor of Medical Oncology
Head of Department of Medical Oncology, Università...
